About

Our mission: design, discover and deliver new medicines

More than 80 percent of validated therapeutic targets are intracellular. Drugging these targets is complicated by the significant barriers to intracellular delivery, including cell membranes and degradative systems, which have largely confined existing intracellular therapies to small molecule drugs.

Driven by a critical need

We recognize the need to develop more sophisticated packaging for therapeutic agents to enable direct transfer to targets, while avoiding immune reaction and internal degradation mechanisms that interfere with successful delivery. This treatment gap drives Vesigen’s development of our novel ARMMs (ARRDC1 Mediated Microvesicles) technology, a class of fusogenic extracellular vesicles that is enabling new therapies to address unmet medical needs.

Advancing therapeutic opportunity

With a seasoned team, we are expanding operations to meet key data milestones and to chart a path to clinical development. The Vesigen team has decades of experience leading scientific advancement and drug development. Supported by our top-tier investors and a prominent scientific advisory board, Vesigen is prepared to deliver on the promise of ARMMs.

Join our team

Explore current opportunities